flâneur

TNIK | Insilico Medicine

insilico.com · 847 words · saved by 1 readers

To main content EN _ FR Main About Pharma.ai Pipeline News & Media Careers Docuthon PreciousGPT Sustainability BACK TO PIPELINE TNIK TNIK Inhibitor: Treating Fibrotic diseases (Phase IIa completed) Assays Completed Wholly-owned and Available for Licensing Phase 1 Clinical Stage Development In vivo efficacy studies with single agent Bleomycin and combo study with Nintedanib & Pirfenidone In vivo PK-PD In vivo PK studies In vivo efficacy studies In vitro ADMET studies Developability/CMC In vitro cell-based Toxicology studies Enzymatic Target Rationale Fibrosis is defined as an excessive deposition of connective tissue components, considered as the endpoint of pathological remodeling. It contributes to the pathogenesis of several chronic diseases and aging related organ damage including that of – skin, lungs, heart, liver, kidney etc. Fibrotic tissue remodeling often leads to organ malfunction and is commonly associated with high morbidity and mortality. It is the result of c

TNIK | Insilico Medicine Back to Pipeline TNIK TNIK Inhibitor: Treating Fibrotic diseases (Phase IIa completed) Assays Completed Wholly-owned and Available for Licensing Phase 1 Clinical Stage Development In vivo efficacy studies with single agent Bleomycin and combo study with Nintedanib & Pirfenidone In vivo PK-PD In vivo PK studies In vivo efficacy studies In vitro ADMET studies Developability/CMC In vitro cell-based Toxicology studies Enzymatic Target Rationale Fibrosis is defined as an excessive deposition of connective tissue components, considered as the endpoint of pathological remodel

related reading